Collectively, the in vivo efficacy studies indicate that AB21 combines with ICIs targeting PD-1 or PD-L1 to improve tumor control that leads to durable antitumor immunity against MC-38 and CT26 tumors. The gene discussed is CD274; the disease is neoplasm.